il 28B polymorphisms and the prognosis for the efficacy of antiviral therapy in viral hepatitis C patients in Uzbekistan
Introduction: By means of the Association for the Study of complete genome there was identified the prognostic value of polymorphisms associated with single-nucleotide substitutions (SNP) in the human genome and located in the region of the gene IL28B/IFN-L3. Hereafter also there were identified SNP in the gene IFN-L4 and there was found a correlation between the population and the spontaneous elimination of HCV infection. Methods: In the studies there was used the materialfrom 135 HCV-infected persons residing on the territory of Uzbekistan. DNA was isolated from peripheral blood mononuclear cells (PBMC), then SNP genotyping of the IFN-L3 gene region (rs8099917, rs12979860) was performed by means of three methods: Invader Plus Assay, TaqMan Assay and direct sequencing. The plot of the IFN-L4 gene (ss469415590) was sequenced. Results: Out of the 135 studied patients, who received antiviral treatment according to the standard scheme Peg-IFN-a in combination with RBVfor 24 and 48 weeks, 87,4% were belonged to the Central Asian (CA) ethnic group and 12.6% - Eastern European (EE). Among the examined cases, there no virological response to antiviral therapy was observed in 21.2% of patients from CA group and 35.3% of EE patients (p <0.32). High association of SNP rs12979860 was observed in the testing of all samples with sustained antiviral response to the therapy (OR, 5.2; 95% CI, 1.9 - 14.6; p <0.004), but the SNP rs8099917 showed a high prognostic significance only in the CA group (OR, 6.9; 95 % CI, 2.6 - 18.0; p <0.002). Allele frequencies IFNL4 SNP rs469415590 were met similarly to SNP rs12979860 in the all studied samples. Conclusions: For the prediction of the outcome ofantiviral therapy in viral hepatitis C among populations of Central Asia, SNP regions and genes IFNL3IFNL4 can be used as markers of genetic factors.